Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Cancer|December 23, 2022
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort studyMonique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk, et al.
British Journal of Cancer|March 16, 2021
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment RegistryJesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.
Fungal Systematics and Evolution|February 15, 2023
New and Interesting Fungi. 5P W Crous, B A D Begoude, J Boers, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.
British Journal of Cancer|March 8, 2022
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
JCO Oncology Practice|August 9, 2022
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort StudyJesper van Breeschoten, Rawa K Ismail, Michel W J M Wouters, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 22, 2025
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced MelanomaSaskia de Groot, Hedwig M Blommestein, Brenda Leeneman, et al.
Cancer|January 10, 2024
BRAF/MEK inhibitor rechallenge in advanced melanoma patientsOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment RegistryRik J Verheijden, Anne M May, Christian U Blank, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|December 23, 2022
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort studyMonique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk, et al.
British Journal of Cancer|March 16, 2021
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment RegistryJesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.
Fungal Systematics and Evolution|February 15, 2023
New and Interesting Fungi. 5P W Crous, B A D Begoude, J Boers, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.
British Journal of Cancer|March 8, 2022
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
JCO Oncology Practice|August 9, 2022
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort StudyJesper van Breeschoten, Rawa K Ismail, Michel W J M Wouters, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 22, 2025
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced MelanomaSaskia de Groot, Hedwig M Blommestein, Brenda Leeneman, et al.
Cancer|January 10, 2024
BRAF/MEK inhibitor rechallenge in advanced melanoma patientsOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment RegistryRik J Verheijden, Anne M May, Christian U Blank, et al.
Pageof 13